The Financial Burden of Rotavirus Disease in Four Countries of the European Union
Identifieur interne : 001420 ( Main/Exploration ); précédent : 001419; suivant : 001421The Financial Burden of Rotavirus Disease in Four Countries of the European Union
Auteurs : Baudouin Standaert [Belgique] ; Olof Harlin [Suisse] ; Ulrich Desselberger [Royaume-Uni]Source :
- The Pediatric infectious disease journal [ 0891-3668 ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Pédiatrie.
English descriptors
- KwdEn :
Abstract
Background: Rotavirus disease is associated with a substantial financial burden. Rotavirus gastroenteritis in children under 5 results in considerable medical resource utilization and burden for parents and society. Methods: For this study a modeling approach was employed to assess the financial burden ofrotavirus disease in 4 European Union countries (Belgium, France, the Netherlands, and the United Kingdom). Both direct medical costs to health authorities and indirect costs borne by society, parents, and employers were calculated. Results: The Purchasing-Power-Parity-adjusted direct cost expressed as a cost per exposure year, per child under 5, was highest in France (∈12.26) and Belgium (∈11.80) compared with the Netherlands (∈8.13) and the United Kingdom (∈7.67). The Purchasing-Power-Parity-adjusted indirect cost was estimated to be highest in the United Kingdom (∈15.47) and the Netherlands (∈15.33) compared with France (∈11.31) and Belgium (∈10.24). The sum of the direct medical and indirect costs of rotavirus disease management was estimated to be ∈23.11 ± ∈0.70/yr per child under 5 years for all 4 countries. Conclusions: In countries where more emphasis was placed on first-line intervention (United Kingdom, the Netherlands), direct costs were lower than in countries where access to second-line healthcare support was more open (Belgium, France). The data suggest that the greater burden of financial responsibility of managing rotavirus disease in children was borne by society (higher in the United Kingdom and the Netherlands than in France and Belgium). In Europe investment in rotavirus disease management is substantial, therefore the medical and economic benefits of a vaccination strategy should be considered to reduce the medical and financial burden associated with acute rotavirus gastroenteritis.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000085
- to stream PascalFrancis, to step Curation: 000064
- to stream PascalFrancis, to step Checkpoint: 000058
- to stream Main, to step Merge: 001423
- to stream Main, to step Curation: 001420
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The Financial Burden of Rotavirus Disease in Four Countries of the European Union</title><author><name sortKey="Standaert, Baudouin" sort="Standaert, Baudouin" uniqKey="Standaert B" first="Baudouin" last="Standaert">Baudouin Standaert</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>GlaxoSmithKline Biologicals</s1><s2>Wavre</s2><s3>BEL</s3><sZ>1 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>GlaxoSmithKline Biologicals</wicri:noRegion></affiliation></author><author><name sortKey="Harlin, Olof" sort="Harlin, Olof" uniqKey="Harlin O" first="Olof" last="Harlin">Olof Harlin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>archimed medical communication AG</s1><s2>Zofingen</s2><s3>CHE</s3><sZ>2 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>archimed medical communication AG</wicri:noRegion></affiliation></author><author><name sortKey="Desselberger, Ulrich" sort="Desselberger, Ulrich" uniqKey="Desselberger U" first="Ulrich" last="Desselberger">Ulrich Desselberger</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Cambridge</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Cambridge</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Angleterre de l'Est</region></placeName><orgName type="university">Université de Cambridge</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0129053</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0129053 INIST</idno><idno type="RBID">Pascal:08-0129053</idno><idno type="wicri:Area/PascalFrancis/Corpus">000085</idno><idno type="wicri:Area/PascalFrancis/Curation">000064</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000058</idno><idno type="wicri:doubleKey">0891-3668:2008:Standaert B:the:financial:burden</idno><idno type="wicri:Area/Main/Merge">001423</idno><idno type="wicri:Area/Main/Curation">001420</idno><idno type="wicri:Area/Main/Exploration">001420</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The Financial Burden of Rotavirus Disease in Four Countries of the European Union</title><author><name sortKey="Standaert, Baudouin" sort="Standaert, Baudouin" uniqKey="Standaert B" first="Baudouin" last="Standaert">Baudouin Standaert</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>GlaxoSmithKline Biologicals</s1><s2>Wavre</s2><s3>BEL</s3><sZ>1 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>GlaxoSmithKline Biologicals</wicri:noRegion></affiliation></author><author><name sortKey="Harlin, Olof" sort="Harlin, Olof" uniqKey="Harlin O" first="Olof" last="Harlin">Olof Harlin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>archimed medical communication AG</s1><s2>Zofingen</s2><s3>CHE</s3><sZ>2 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>archimed medical communication AG</wicri:noRegion></affiliation></author><author><name sortKey="Desselberger, Ulrich" sort="Desselberger, Ulrich" uniqKey="Desselberger U" first="Ulrich" last="Desselberger">Ulrich Desselberger</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Cambridge</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Cambridge</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Angleterre de l'Est</region></placeName><orgName type="university">Université de Cambridge</orgName></affiliation></author></analytic><series><title level="j" type="main">The Pediatric infectious disease journal</title><title level="j" type="abbreviated">Pediatr. infect. dis. j.</title><idno type="ISSN">0891-3668</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The Pediatric infectious disease journal</title><title level="j" type="abbreviated">Pediatr. infect. dis. j.</title><idno type="ISSN">0891-3668</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Costs</term><term>Europe</term><term>Infection</term><term>Pediatrics</term><term>Rotavirus</term><term>Viral gastroenteritis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Infection</term><term>Europe</term><term>Coût</term><term>Pédiatrie</term><term>Rotavirus</term><term>Gastroentérite virale</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Pédiatrie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Rotavirus disease is associated with a substantial financial burden. Rotavirus gastroenteritis in children under 5 results in considerable medical resource utilization and burden for parents and society. Methods: For this study a modeling approach was employed to assess the financial burden ofrotavirus disease in 4 European Union countries (Belgium, France, the Netherlands, and the United Kingdom). Both direct medical costs to health authorities and indirect costs borne by society, parents, and employers were calculated. Results: The Purchasing-Power-Parity-adjusted direct cost expressed as a cost per exposure year, per child under 5, was highest in France (∈12.26) and Belgium (∈11.80) compared with the Netherlands (∈8.13) and the United Kingdom (∈7.67). The Purchasing-Power-Parity-adjusted indirect cost was estimated to be highest in the United Kingdom (∈15.47) and the Netherlands (∈15.33) compared with France (∈11.31) and Belgium (∈10.24). The sum of the direct medical and indirect costs of rotavirus disease management was estimated to be ∈23.11 ± ∈0.70/yr per child under 5 years for all 4 countries. Conclusions: In countries where more emphasis was placed on first-line intervention (United Kingdom, the Netherlands), direct costs were lower than in countries where access to second-line healthcare support was more open (Belgium, France). The data suggest that the greater burden of financial responsibility of managing rotavirus disease in children was borne by society (higher in the United Kingdom and the Netherlands than in France and Belgium). In Europe investment in rotavirus disease management is substantial, therefore the medical and economic benefits of a vaccination strategy should be considered to reduce the medical and financial burden associated with acute rotavirus gastroenteritis.</div></front></TEI><affiliations><list><country><li>Belgique</li><li>Royaume-Uni</li><li>Suisse</li></country><region><li>Angleterre</li><li>Angleterre de l'Est</li></region><settlement><li>Cambridge</li></settlement><orgName><li>Université de Cambridge</li></orgName></list><tree><country name="Belgique"><noRegion><name sortKey="Standaert, Baudouin" sort="Standaert, Baudouin" uniqKey="Standaert B" first="Baudouin" last="Standaert">Baudouin Standaert</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Harlin, Olof" sort="Harlin, Olof" uniqKey="Harlin O" first="Olof" last="Harlin">Olof Harlin</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Desselberger, Ulrich" sort="Desselberger, Ulrich" uniqKey="Desselberger U" first="Ulrich" last="Desselberger">Ulrich Desselberger</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001420 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001420 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:08-0129053
|texte= The Financial Burden of Rotavirus Disease in Four Countries of the European Union
}}
| This area was generated with Dilib version V0.6.25. |  |